Acadia Pharmaceuticals (ACAD) Retained Earnings (2010 - 2026)
Acadia Pharmaceuticals' (ACAD) quarterly Retained Earnings came in at -$1.8 billion in Q1 2026, down 414230.21% year-on-year from N/an in Q1 2025, and down 125342.15% quarter-over-quarter from $1.4 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Retained Earnings (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$1.8 billion for Q1 2026.
- On a quarterly basis, Retained Earnings fell 414230.21% year-over-year to -$1.8 billion in Q1 2026; TTM through Mar 2026 was -$1.8 billion, a 414230.21% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, up 394.86% from the prior year.
- Retained Earnings retreated to -$1.8 billion in Q1 2026 per ACAD's latest filing, from $1.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.4 million in Q4 2025 and bottomed at -$2.4 billion in Q4 2023.
- The 5-year median for Retained Earnings is -$339000.0 (2024), against an average of -$941.1 million.
- Across the five-year window, Retained Earnings jumped 394.86% in 2025 and plunged 414230.21% in 2026, its largest moves.
- Year by year, Retained Earnings stood at -$2.4 billion in 2022, then slipped by 2.59% to -$2.4 billion in 2023, then surged by 100.01% to $292000.0 in 2024, then surged by 394.86% to $1.4 million in 2025, then tumbled by 125342.15% to -$1.8 billion in 2026.
- Per Business Quant, the three latest ACAD Retained Earnings figures stand at -$1.8 billion (Q1 2026), $1.4 million (Q4 2025), and $989000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Acadia Pharmaceuticals | 4.23 Bn | 3.38 Bn | 243.27 Mn | -1.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.81 Bn |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 989,000.00 |
| Jun 30, 2025 | 406,000.00 |
| Mar 31, 2025 | 437,000.00 |
| Dec 31, 2024 | 292,000.00 |
| Sep 30, 2024 | 858,000.00 |
| Jun 30, 2024 | -339,000.00 |
| Mar 31, 2024 | -229,000.00 |
| Dec 31, 2023 | -2.43 Bn |
| Sep 30, 2023 | -319,000.00 |
| Jun 30, 2023 | -2.41 Bn |
| Mar 31, 2023 | -2.41 Bn |
| Dec 31, 2022 | -2.37 Bn |
| Sep 30, 2022 | -1.37 Mn |
| Jun 30, 2022 | -2.30 Bn |
| Mar 31, 2022 | -2.27 Bn |
| Dec 31, 2021 | -2.15 Bn |
| Sep 30, 2021 | -2.11 Bn |
| Jun 30, 2021 | -2.10 Bn |